Background
Methods
Results
Epidemiology (32)
Pre-2008 (22 studies)
Incidence (2 studies)
Prevalence (20 studies) (prisoners =3 studies, PWUD = 7 studies, PWID = 8 studies)
Prisoners
At -risk population associated with PWUD (2 studies)
Date and author | Setting | Sample (n) | Data collection | Design | Main results | |
---|---|---|---|---|---|---|
Prisoners | ||||||
[18] | 2000 Alwright et al | National Multi-site 9/15 prison locations | Prisoners (1205; m = 1148) | Sept – Nov 1998 | Cross-sectional randomised prevalence study | Anti-HCV = 37% (95% CI = 34.3 to 39.9%) |
• 80% among prisoners with a Hx of IDU | ||||||
• 60% of women and 42% of men had Hx of IDU | ||||||
• 20% first IV in prison and 71% shared needles | ||||||
Significant risk factors (p < 0.05): • IDU • Hx of sharing while in prison | ||||||
[16] | 2000 Thornton et al | National Multi-site 9/15 prison locations | Prisoners (1205; m = 1148) | Sept – Nov 1998 | Cross-sectional study comparing reported vs actual HCV status | Anti-HCV = 37% |
Self-report anti-HCV = 19% | ||||||
• Among those self-reporting being anti-HCV positive, 5% were negative on oral fluid assay. | ||||||
• Among those reporting a previous negative result, 37% were positive on oral fluid assay. | ||||||
[38] | 2001 Long et al | National Multi-site 5 of 7 committal prisons | Prisoners (607; m = 555) | April–May 1999 | Cross sectional prevalence study on new entrants and risk factors | Anti-HCV = 22% (CI: 19–25%) |
• anti HCV = 72% (Hx of IDU) | ||||||
• anti HCV = 3% (Never in prison) | ||||||
Significant risk factors (p < 0.05): • IDU | ||||||
PWUD | ||||||
[39] | 2001 Fitzgerald | Dublin Multi-site 5 Drug Treatment centre sites | Opiate users on MMT > 4 weeks (138/715; m = 99) | 1997 | Cross-sectional retrospective prevalence study - randomised sample (chart review) | Anti-HCV = 78.8% • 60% screened • Among those < 25 yrs., anti-HCV prevalence decreases to 52% |
[42] | 2003 Cullen et al | ERHA Multi-site 42 GP locations | Drug users on MMT (531; m = 443) | Not reported | Cross sectional prevalence study and associated risks | Anti-HCV = 78% |
• 67% screening documented • 193 had screen completed by GP, 74 another service and 113 no screen but self-report from patient | ||||||
• Predictors of being screened | ||||||
• Hx of imprisonment | ||||||
• documented HIV neg • Hx of IDU | ||||||
Significant risk factors (p < 0.05): | ||||||
• age > 26 | ||||||
• Hx of IDU | ||||||
• Hx of imprisonment drug use prior to 1989 | ||||||
• HIV pos/HBV pos | ||||||
[41] | 2004 Moloney et al | Dublin Single-site Community drug treatment programme for young people | Adolescent drug users (54; heroin smoking = 64%) | 1998–2001 | (Letter – response to Kavanagh et al. 2003) | Anti-HCV = 27% Anti-HCV among declared injectors = 55% Mean duration of injecting: |
• Anti-HCV positive = 1.42 yrs. | ||||||
• Anti-HCV negative = 1.16 yrs. | ||||||
[37] | 2005 Grogan et al | Dublin Multi-site Community drug treatment centres (21) | Drug users on MMT (358; m = 214) | 2001 | Cross-sectional- retrospective (one in four consecutive sampling) | Anti-HCV = 66% |
Incidence 24,5 per 100 years | ||||||
88% tested for HCV | ||||||
Significant risk factors (p < 0.05): | ||||||
• age > 25 | ||||||
[44] | 2007 Cullen | Multi-site 25 GP practices Dublin | PWUD on MMT (196; m = 100) | Cross-sectional Prevalence | Anti-HCV = 69% | |
• 77% screened for HCV | ||||||
• 36% of those anti-HCV were tested for HCV-RNA | ||||||
• 30% were referred to hepatology | ||||||
• 24% attended the clinic | ||||||
• 13% had a liver biopsy | ||||||
• 3% had started treatment | ||||||
[54] | 2008 O’Carroll et al. | DublinMulti-site | Homeless (393; m = 61%; drug users = 64%) | 2005 | A census of homeless adults (researcher administered questionnaire) | Anti-HCV = 36% (95% CI: 31–41%) |
[40] | Noonan et al. 2009 | Single site NDTC | Drug users receiving MMT (103; m = 67) | Sept-Dec 2002 | Cross-sectional survey | Anti-HCV = 81.6% (untested = 2.8%) |
HCV RNA = 15.6% (untested = 65%) | ||||||
• Most of the study participants had accurate self-reported of HCV status | ||||||
Problem drinking: | ||||||
• Prevalence (audit score) = 41% (95% CI 33–51%). | ||||||
• 98% agreed that ‘alcohol may worsen HCV related liver disease’ • 92% agreed that ‘reducing | ||||||
• alcohol consumption may help HCV related liver disease’. | ||||||
PWID
| ||||||
[45] | 1983 Fielding et al. | Dublin Single site Hospital | PWID with acute hepatitis undergoing biopsy (27; m = 22; mean age = 20.8 yrs.;Hx IDU = 6–120 months) | Jan-April 1981 | Cross-sectional prevalence study | 90% had exposure to non-A non-B (HCV) |
[48] | 1995 Smyth et al. | Dublin Single site Specialist drug treatment service (NDTC) | PWID on OST (272; m = 194) | Aug 1992–1993 | Cross-sectional prevalence study | Anti-HCV = 84% |
Significant risk factors (p < 0.05): | ||||||
• male gender | ||||||
• > 2 years Hx IDU | ||||||
[17] | 1998 Smyth et al. | Dublin Single site Specialist drug treatment service (NDTC) | PWID - new entrants to treatment (733; m = 529) | 1992–1997 | Cross-sectional prevalence study | Anti-HCV = 61.8% |
(95% CI = 58.3–65.3) Significant risk factors (p < 0.05): | ||||||
• older age | ||||||
• longer HX of IDU | ||||||
• IDU before 1990 | ||||||
• daily expenditure > 65 punts | ||||||
[47] | 1999 Smyth et al | Dublin Single site Specialist drug treatment Service (NDTC) | PWID - new entrants with HX IDU of < 25 months (353; m = 241) | July 1993- Dec 1996 | Cross-sectional prevalence study | Anti-HCV = 52.1% • ↓ risk for those starting IDU after 1993 and with IDU < 13 months |
[55] | 2000 Smyth et al | Dublin Single site Specialist drug treatment service (NDTC) | PWID, first time attendees (119; m = 84) | July 1996–January 1997 | Prospective evaluation of an HCV testing algorithm | Anti-HCV = 54% • 21/119 completed assessment |
• 48 tested for HCV | ||||||
• 13/26 HCV infected left OST treatment before receiving result | ||||||
• 4/19 attended on-site hepatology services | ||||||
[53] | 2000 Healy et al | Dublin Single site Hospital (Infectious paediatric OPD) | HCV+ mothers of infants referred to Paediatric infectious disease service (296; PWID = 244) | 1994–1999 | Cross-sectional Prevalence | HCV RNA: 55% (84 tested) • 82% infected via IVDU |
[49] | 2003 Kavanagh et al | Dublin Single-site | PWID (94 - prevalence study; m = 63) PWID = 5519 (mathematical modelling) | November 2001 | Prevalence of HCV and its Prognostics/co-factors Mathematical modelling to estimate national HCV burden | Anti-HCV = 74.5% HCV RNA = 41.5% • Genotype 1 = 66.6% |
• Genotype 2 = 2.6% | ||||||
• Genotype 3 = 25.6% | ||||||
Modelling predictions: | ||||||
• HCV cirrhosis = 1214 cases (20 yrs.) | ||||||
• HCC = 35 per annum | ||||||
• Hepatic decompensation = 60 per annum | ||||||
• Liver related deaths = 50 per annum | ||||||
[36] | 2003 Smyth et al | Dublin Single site Specialist drug treatment service (NDTC) | HCV negative PWID (313; Follow up repeat HCV test = 100) | Nov 1992 – September 1998 | Retrospective cohort study Incidence of HCV infection | HCV seroconversion = 67% Incidence = 66 per 100-person years (CI: 51–84 per 100-person years) |
Of 74 patients who were retested within 24 months | ||||||
• HCV seroconversion = 61% • Incidence = 100 infections/100 | ||||||
• person years (95% CI: 73/100 to 134/100 person years). | ||||||
Significant risk factors (p < 0.05): • Hx IDU | ||||||
• Hx imprisonment | ||||||
[51] | 2005 Smyth et al | Dublin Multi-site (10) Community drug treatment clinics (7) Residential drug treatment centres (2) NDTC (1) | PWID - IV in the past 6 months / not tested for HCV (159) | Cross-sectional survey | Anti-HCV = 61% | |
Predictors of positive test result (p < 0.05): • increased total number of lifetime injecting episodes | ||||||
• closer social relationships with other IDUs | ||||||
• injecting in the home of other IDUs | ||||||
Non-predictor of positive result (p > 0.05): • Frequency of recipient syringe sharing | ||||||
• backloading | ||||||
• sharing of injecting paraphernalia | ||||||
[56] | 2006Cullen | Dublin Multi-site 26 GP practices | PWID-GP | 2005 (6-month period) | Cluster randomised trial /evaluating the effects of HCV guidelines | Intervention group • ↑ HCV screening (OR = 3.76; 95% CI = 1.3 to 11.3) |
• ↑ referral to a hepatology clinic (p = 0.06) | ||||||
[6] | 2012 Thornton et al | National | General population (6387; m = 4024) | 1989–2009 | National HCV prevalence study using data collected from NVRL (1989–2004) notification data (2004–2009) Mathematical modelling | General population estimate for chronic HCV infection = 20,000–50,000 (0.5–1.2%). • 10,000 people diagnosed anti-HCV between 1989 and 2004, peaking in 2000. |
• Genotype 1 = 55% and Genotype 3 = 39%. | ||||||
• Drug use most likely risk (80%). | ||||||
• Median age of diagnosis is 28. • 70% of those infected though drug users were male. • Median age at diagnosis for those infected through drug use = 25 years for males and 23 years for females. |
Post 2008 (10 studies)
Incidence (1 study)
Prevalence (9 studies) (Prisoner = 2 studies, PWUD = 6 studies, PWID = 1 study)
Prisoner
PWID (1 study)
Date and author | Setting | Sample (n) | Data collection | Design | Main results | |
---|---|---|---|---|---|---|
Prisoners | ||||||
[13] | 2014 Drummond et al | National Multi-site Prisons (15) | Prisoners (817; m = 772; Hx IDU = 26%) | 2011 | Observational Cross-sectional prevalence study including self- administered drug and risk questionnaire | Anti-HCV prevalence = 13% Significant risk factors (p < 0.05): • Hx of IDU and sharing drug taking equipment • Older age • female gender • prison tattoo |
[57] | 2014 Galander | Dublin Single site Prison | Male prisoners on MMT (119) | October 2011 | Patient Survey Retrospective chart review | Anti-HCV = 38% • Anti-HCV negative = 33% • Unknown HCV status = 29% • Number anti-HCV on treatment = 0 |
PWUD | ||||||
[62] | 2014 McCormick et al. | Dublin Single site Drug treatment clinic | Drug Users fibroscaned attending MMT (84; m = 66) | Letter – reporting on five year follow up study | Anti-HCV = 74.4% HCV-RNA = 58.3%, Heavy alcohol use = 37% Five-year mortality = 15% (Liver related deaths = 6; probable liver related = 1; drug overdose = 5; laryngeal carcinoma = 1) • 5/6 patients who died of liver disease, were HCV RNA-positive with heavy alcohol use • Mean liver stiffness values were higher in patients who died compared with survivors (28.5 kPa ±7.9 vs. 9.0 ± 1.5, P = 0.0045) • Mean liver stiffness values were higher in patients with liver-related death compared with survivors (50.6 ± 11.2, P < 0.0002). • 12 patients with fibroscan score > 14 kPa, (7 died; 4 developed liver failure) • Fibroscan scores were higher in patients with a history of heavy alcohol use (23 ± 4.5 vs. 5.6 ± 0.3, P < 0.0001). • A single liver stiffness measurement was highly predictive of liver-related mortality | |
[58] | Ryan and Ryan 2014 | Limerick Single site Community drug treatment centre | Drug users on MMT(174) | 2010–2012 | Retrospective prevalence study (log review) | Anti-HCV 2010 = 6% Anti-HCV 2011 = 13% Anti-HCV 2012 = 24% On average 58 HCV tests ordered annually |
2014 Horan | Cork Single site Community drug treatment Centre | Drug users on MMT (30) | 2-week periods ×2 separated by a few months in 2014 | Chart audit of HCV screening measuring the effect of chart labelling (star) | • No evidence of HCV screen = 50% • Follow up audit = 72.7% had evidence of documentation of an HCV screen | |
Burke M. Audit of HCV screening using retrospective patient records [Unpublished audit] | Dublin Multi-site Community drug treatment centres (23) | PWUD - Opioid users on MMT (358; 40% of eligible population; PWID = 79%) | 2015 | Audit of HCV screening using retrospective patient records | Anti-HCV = 66% HCV RNA = 65% • Screening uptake = 95% • RNA tested = 208 | |
[63] | 2016 McCombe et al. | Dublin Multi-site GP (16) | PWUD attending primary care for MMT (106) | 2015 | Commentary (letter) Secondary analysis of data collected during a feasibility study of an alcohol brief intervention for patients attending primary care for MMT | Anti-HCV = 51% • HCV tested = 99% • Self-reported HCV treatment = 19% Problem alcohol use = 45% • 37% were anti-HCV and had problem alcohol use Patients’ knowledge of HCV care can best be optimised through community-based approaches to HCV treatment |
[59] | Keegan et al. 2017 | Dublin Single site Community drug treatment centre | PWUD attending for MMT (228; m = 168) | January 2015 | Cross sectional prevalence study (retrospective chart review) with associated risk factors | Anti-HCV = 63.6% with no significant gender difference (p = 0.717) Significant risk factors for HCV infection (p < 0.05): • age • age of first drug use • age of first injection • type of first drug used • early age of MMT entry Those with no IDU had decreased odds of being HCV positive by 91.1%. |
(Burke M: Audit of HCV screening using retrospective patient records, unpublished) | Dublin Multi-site Community drug treatment centre (23) | PWUD on MMT (282; PWID = 79%) | 2016 | Audit; Retrospective chart review | Anti-HCV = 79% HCV RNA = 65% | |
[60] | 2017 Murtagh et al. | Dublin GPs Multi-site (n = 14) | Drug users on OST (133; m = 81) | 2017 | Cross-sectional Prevalence | Anti-HCV = 77.2% • 92.5% had been screened for HCV • 14 (14.7%) patients previously diagnosed with HCV had ever initiated HCV treatment |
[9] | 2017 Garvey et al | National | General population > 18 years (3795; m = 1860) | 2014–2016 | Anonymised and randomised laboratory analysis of residual serum samples at the NVRL | Anti-HCV = 1.4% HCV RNA = 0.57% (95% CI: 0.40–0.81%) • higher in men (0.91%; 95% CI: 0.61–1.4%) • east of the country (1.4%; 95%CI: 0.99–2.0%) • 0–39 years (1.1% (95% CI: 0.59–2.0%) • 40–49 years (1.1% (95% CI: 0.64–1.9%) • Men born between 1965 and 1984 from the east of the country have the highest rate of chronic HCV infection. |
PWID | ||||||
[61] | 2014 O’Connor et al | Dublin Single site Hospital ED | PWID (146; m = 101) | January – March 2010 | Prospective observational study | Anti-HCV = 74% • High levels of comorbid illness |
[19] | 2016 Carew et al. | National | PWID registered on NDTRS (14,320; m = 10,597) | 1991–2014 | Mathematical modelling | Number of PWID with HCV infection = 12,423 (95% CI 10,799-13,161) Number of PWID with chronic HCV infection = 9317 (95% CI 8022-9996) • Estimated number of new infections peaked in 1997. • By 2014, more than one quarter (27.0%) of PWIDs with chronic HCV infection were estimated to have been infected for 0–10 years, 43.4% for 11–20 years, 22.8% for 21–30 years and 6.7% for over 30 years. |
HCV risk factors
HCV screening uptake
Identified gaps
Guidelines and policy (8 studies)
Date and author | Setting | Sample (n) | Data collection | Design | Main results | |
---|---|---|---|---|---|---|
[67] | 2004 Dublin Area Hepatitis C Initiative Group | ERHA | GPs | 2001–2002 | Descriptive study reporting on HCV management guideline development for GPs | The guidelines cover advice to GPs on all aspects of care of patients at risk of HCV, including • general and preventative care • care of other bloodborne and hepatotoxic viruses • factors to be considered and appropriate evaluation prior to referring a patient for assessment at a hepatology unit. |
[66] | 2004 Hepatitis C Scientific Advisory Subgroup of the Blood Borne Virus Forum and the Eastern Regional Health Authority | ERHA | 16 workshops with service planners, health and social care professionals and service users (70 | 2004 | A regional hepatitis C strategy document using open space technology | Reported on: • health promotion • role of the media • service provision • research, policy and planning • education and training, • liaison • key workers • co-ordination and collaboration • accessing services • psychological and complementary therapies |
[72] | 2006 Long | National | Drug users | 1995–2005 | Review | Reports on • 9 prevalence studies • 7 studies identifying risk factors |
[70] | 2009 IPS | Dublin | Prisoners | – | Guidelines | Provide prisoners • general health information • advice and testing • referral to appropriate specialist services in relation to HCV where clinically indicated • treatment and support for those chronically infected. |
[14] | 2012 HSE | National | PWID & prisoners | 2007 | First national strategy | • Reviewed and updated recommendation from the 2004 ERHA report. • Developed 36-point action plan Prioritising recommendations for 2011–2012 in the areas of HCV surveillance, education, prevention and treatment. |
[68] | 2014 DOH | National | HCV infected patients | – | Guidelines | Recommendations: • HSE establish a Hepatitis C Treatment Programme with a strong governance and management structure • Provide drug treatment to those with greatest clinical need as a priority and treat as many patients as possible with the available resources |
[69] | HSE 2017 | National | OST Guidelines | • All drug users (including non-PWID) should be screened for HCV. • Anti-HCV patients should be tested for HCV-antigen and LFTs • all antigen positive patients should be referred to specialist services for PCR, fibroscanning and consideration for treatment. • All patients at risk of HCV infection should be given information and advice on the disease and how it is transmitted. • IDU and alcohol misuse should not exclude patients from treatment. • Risks of concurrent alcohol use should be explained to anti-HCV patients. |
Treatment outcomes (13 studies)
Date and author | Setting | Sample (n) | Data collection | Design | Main results | |
---|---|---|---|---|---|---|
[50] | 2005 Keating et al | Dublin Multi-site 5 drug treatment centres | PWID mono-infected with HCV (496; m = 341; 2 years follow up = 127) | Jan 1997- Nov 2001 Repeat follow up testing in 2003 | Cross-sectional prospective study on HCV clearance | HCV RNA: • Negative = 38% (self-clearance) (f = 47.4%; m = 34.5%) • Follow up (2 yrs) = 82.2% sustained viral clearance • Overall viral clearance = 31.1% • Genotype distribution (1 = 48.8%; 3 = 48.5%) |
[76] | 2006 Hopkins | Single site Hospital | Co-infected with HIV and HCV patients with CD4 counts > 200 cells/mL (45; m = 39; PWID = 58%) | June 2001–2003 | Open-label, prospective study | SVR = 53% • Genotype 2 and 3 patients had a significantly higher SVR (75%) than genotype 1 (19%) • Adverse events occurred frequently |
[74] | 2011 Kieran et al | Dublin Single-site Hospital Integrated HIV/HCV clinic | Co-infected attendees (386; m = 278) | October 2008–January 2009 | Retrospective chart review | 202/386 – referred to co-infected clinic, with 107 completing treatment • SVR = 44% (similar outcomes for PWID compared to patients with other transmission risks) Associations with missed appointments • younger age • active IDU • advanced HIV infection Dedicated co-infection clinics lower the threshold for treatment and improve management of liver disease in co-infected patients |
[75] | 2011 Lowry et al | Dublin Single-site Hospital | HCV mono-infected patients referred (588 individuals (repeat referrals = 742 cases); m = 388; PWID = 74%) | 2000–2007 | Retrospective chart review | SVR = 74% • History of IDU was not a significant predictor of lower therapy completion rate or achievement of SVR In total, 451 (61%) dropouts occurred • 141 (19%) failed to attend their initial appointment • 180 dropped out from early outpatient management • 29 failed to attend liver biopsy • 81 defected from subsequent outpatient follow-up. Statistically significant associations with history of injection drug use • dropout immediately after the referral (P < 0.001) • dropout from early outpatient management (P < 0.001) • dropout over entire span of disease management (P < 0.001) Male sex was also associated with dropout from disease management (P < 0.05) |
[52] | 2012 Kelly and Kelly | Dublin Single site GP | PWID (82; m = 62%) | 1985–2010 | Longitudinal cohort study | Anti-HCV = 33% at 10 yrs. (survivors) Anti-HCV = 40% at 25 yrs. (survivors) • 63% of the cohort had died by 2010, of which 26 were attributed to HIV disease • Median survival time for those ant-HCV = 21 years (95% CI 15.5–26.5) which was significantly lower than the median survival time for drug users with a negative hepatitis C status. (p = 0.006) |
[77] | 2017 Elsherif et al | Dublin Single-site Hospital | HCV infected patients (1000; Former PWID (> 6 months) = 608; Recent PWID (< 6 months) = 85; Non-drug users = 307) | 2002–2012 | Retrospective chart review | SVR in PWID = 64.2% • No significant compared to non-PWID (60.9%) [RR = 1.05, 95% CI 0.95 ± 1.17] • There was no significant difference in SVR rates between the groups controlling for genotype (48.4% vs 48.4% for genotype 1; 74.9 vs 73.3% for genotype 3). • No significant difference in treatment non-adherence between the groups (8.4% in PWID vs 6.8% in non-PWIDs; RR = 1.23, CI 0.76 ± 1.99) • Former and recent PWID had similar adherence rates. |
HCV -related health issues (8 studies)
Date and author | Setting | Sample (n) | Data collection | Design | Main results | |
---|---|---|---|---|---|---|
[80] | 2001 Goulding et al | Dublin Single-site Hospital | Patients with chronic HCV infection (77; m = 17; PWID = 25) | Cross-sectional Prevalence of rheumatological disease, anxiety and depression and relationship to mode of acquisition | Anxiety and depression scores were significantly higher in IVDUs (P = 0.005) compared with controls. | |
[82] | 2005 Golden et al | Dublin Single-site Hospital | HCV infected patients awaiting interferon treatment (90; m = 67; 47% PWID) | Prevalence of mood disorder and associated risks using a self-completed structured questionnaire | Depressive disorders: • 1-month prevalence = 21% (72% previously undiagnosed) • Current MMT strongly associated with risk of depression (OR, 5.0; 95% CI, 1.08–23.0). • After adjustment for age and sex, depression was associated with poorer work and social adjustment, lower acceptance of illness, higher illness stigma, poorer reported thinking and concentration, and higher levels of subjective physical symptoms (all P < .05) Anxiety disorders: • 1-month prevalence = 24% (86% previously undiagnosed) • Anxiety disorders were uncorrelated with any risk factor. | |
[78] | 2018 Mc Kiernan et al | Prisons Multi-site Community Single site (hospital) | HCV infected prisoners referred for HCV treatment (510; Treatment outcomes = 104) | 2010–2018 | Retrospective record audit Comparisons between community and prison populations | SVR prison = 90.3% SVR community = 87.5% Referrals: • Mountjoy = 265 • Wheatfield = 173 • Midlands = 33 • Portlaois =15 • Limerick =6 • Others =11 |
Qualitative research reporting on patients’ and health providers’ experiences
Date and author | Setting | Sample (n) | Data collection | Design | Main results | |
---|---|---|---|---|---|---|
[43] | 2005 Cullen et al | Dublin Single site General practice | Heroin users - past history (25) | 2002 (6 months) | Mixed methods using interviewer-administered semi-structured questionnaire | Anti-HCV =88% • Follow up investigations for HCV =8 • Treatment = 1 • 100% aware of HCV • 22/25 consulted healthcare professional about HCV • 21/25 knew HCV infection was caused by injecting • High awareness of harm reduction measures and health implications of HCV • Negative experiences of diagnosis, assessment and treatment |
[85] | 2005 Dillon | Dublin Multi-site 4 prisons | Prison officers | Cross sectional survey | • 87% reported not knowing enough about these diseases to enable them to take the necessary precautions at work • Longer serving and senior officers were less fearful and less anxious about contracting the infections • Officers who had received hepatitis B vaccination were no less worried about hepatitis B than unvaccinated colleagues • Training on blood borne viruses had little effect on prison officers’ knowledge or perception of blood borne viral infections | |
[81] | 2006 Golden | Dublin Single-site Hospital | HCV infected patients awaiting treatment (87; m = 64; PWID = 46%) | Prevalence of illness-related stigma and mood disorders using standardised instruments | • Fear of disclosure combined with social isolation and social rejection • Stigma was higher in those in manual occupations and the unemployed than in those in non-manual occupation • High levels of disease-associated stigma in those with disease associated with IDU and iatrogenic disease caused by transfusion or anti-D blood products • Stigma was associated with depression (OR = 1.4) • Stigma was also associated with poorer work and social adjustment, lower acceptance of illness, higher subjective levels of symptoms and greater subjective impairment of memory and concentration. These associations were replicated in the non-depressed subsample. • Strong link between stigma and well-being in hepatitis C | |
[83] | 2010 Swan et al | Dublin Multi-site (7) Drug treatment clinic (2) GP (1) Community drop in (1) Hepatology (2) ID clinic (1) | PWID (36; m = 28) | 2007–2008 | In-depth one-to-one interviews using grounded theory methodology | Anti-HCV = 91% HIV co-infected = 11% Barriers to HCV screening and treatment: • Perceptions of HCV infection as relatively benign • fear of investigations and treatment including liver biopsy and interferon • feeling well • limited knowledge of testing sites • not being referred for specialist investigations • ineligibility for treatment • competing priorities (employment, education, and addiction). Facilitators to HCV screening and treatment: • relationships with health care providers • trust in providers • concern for the service-user • continuity of care • education on HCV infection, investigations, and treatment • becoming symptomatic • responsibilities for children • wanting to move on from drug use |
[84] | Whitaker et al. 2011 | Dublin | Drug using sex workers (35; m = 4) | One-to-one in-depth interviews | Multiple layers of stigma were reported, linked to sex work, drug use (including IDU) and having contracted HIV or HCV • Stigma was powerfully reinforced by the language routinely used by health professionals. | |
• To improve the effectiveness of harm-reduction interventions, it is recommended that service providers change their language, in particular in recognition of the human dignity of these clients, but also to help attract and retain drug users in services, and to help reduce the unacceptable mortality levels among drug users. | ||||||
[73] | 2017Crowley et al | Dublin Single site Community drug treatment centre | PWID attending community fibroscan clinic (68) | 2017 | Mixed methods Researcher administered questionnaire | Attendance = 90% • high levels of unemployment (90%) and homelessness (40%) |
• higher fibroscan scores (> 8.5Kpa) were associated with longer time since diagnosis (p = 0.016). | ||||||
Patient identified barriers to engagement: | ||||||
• alcohol and drug use | ||||||
• fear of HCV treatment and liver biopsy | ||||||
• imprisonment | ||||||
• distance to hospital | ||||||
• early morning appointments. | ||||||
Patient identified enablers: • afternoon appointments | ||||||
• enhanced prison referral mechanisms into the community Fibroscan unit | ||||||
• location of services within the addiction treatment and detoxification services | ||||||
[79] | 2017 Ni Cheallaigh et al. | National Multi-site Community drug treatment centres, homeless hostels, GPs | Study sites: Pilot sites (4): 2 Dublin based community drug treatment centres, 1 Waterford based; 1 Dublin based homeless hostel 10 interviewees from 8 sites at baseline. 6 participants in pilot programme at study completion | Mar-Oct 2015 | Purposive sampling | Estimated HCV prevalence in GP practices = 1–10% |
Estimated chronic prevalence in pilot sites = 15–75% | ||||||
• PWID were identified as the main group facing barriers to accessing specialist HCV care. | ||||||
• State-employed doctors and nurses were successfully recruited to participate in the project. | ||||||
• GPs did not participate, due mainly to a lack of time and the absence of reimbursement for participation. | ||||||
• Benefits to practitioners and their patients were reported. Participants expressed interest in continued engagement with similar multidisciplinary, multisite educational interventions in the future. |